XML 53 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborations and Other Arrangements (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue $ 6,941,600,000 $ 6,772,800,000 $ 21,239,600,000 $ 20,318,500,000  
Remaining contract liabilities 232,500,000   232,500,000   $ 262,600,000
Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 573,300,000 390,400,000 1,453,700,000 1,058,900,000  
Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 193,000,000.0 192,800,000 558,700,000 650,100,000  
Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 103,800,000 96,100,000 293,000,000.0 279,900,000  
Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 182,900,000 406,900,000 624,700,000 809,100,000  
COVID-19 antibodies          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 386,600,000 217,100,000 1,985,500,000 1,176,200,000  
Tyvyt®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue 76,800,000 $ 125,600,000 235,800,000 $ 340,200,000  
Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Remaining contract liabilities 0   0    
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Jardiance          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 121,200,000   121,200,000   136,100,000
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Basaglar          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements (135,300,000)   (135,300,000)   (149,300,000)
Milestone Payments, Development and Regulatory, Capitalized (Deferred), Cumulative | Trajenta          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 69,600,000   $ 69,600,000   88,500,000
Royalty Agreement Terms | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Collaborative arrangement, rights and obligations, percentage (up to)     20.00%    
Milestone Payments, Capitalized as Intangible Assets | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 330,000,000   $ 330,000,000   260,000,000
Milestone Payments, Capitalized as Intangible Assets | Tyvyt®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 120,000,000   120,000,000   $ 40,000,000
Milestone Payments, Sales-based | Olumiant®          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 100,000,000   100,000,000    
Milestone Payments, Sales-based | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 1,250,000,000   1,250,000,000    
Milestone Payments, Sales-based | Lebrikizumab | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 1,030,000,000.00   1,030,000,000.00    
Milestone Payments, Success-based Regulatory and Sales-based | Tyvyt® | Innovent Biologics, Inc.          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 115,000,000   115,000,000    
Milestone Payments, Development and Regulatory | Lebrikizumab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements 85,000,000   85,000,000    
Milestone Payments, Development and Regulatory | Lebrikizumab | Roche          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential achievements $ 180,000,000   $ 180,000,000